The "Europe Candidiasis Market and Competitive Landscape 2021" report has been added to ResearchAndMarkets.com's offering. Europe Candidiasis Market and Competitive Landscape 2021, provides comprehensive
It is estimated that 80% of women will suffer from vaginal candidiasis at least once in their lives. In addition to superficial infections, which can be oral or vaginal and do not usually have a serious prognosis, fungi of the Candida genus can cause systemic diseases in immunocompromised individuals and these are fatal in 40% of cases.
A phase 3 trial indicates the drug is safe and effective in treating acute and recurrent cases of acute vulvovaginal candidiasis, and preventing recurrence of VVC episodes.